Nasdaq 100 Stocks SEC Filings — February 23, 2026

Timely Item 2.02 earnings disclosure (materiality 7/10) with neutral sentiment and low risk signals operational stability, no disclosed dilution or negative metrics [NEUTRAL-to-BULLISH]

Standard earnings 8-K (Item 2.02, materiality 5/10, low risk) without adverse metrics indicates steady financial condition reporting [NEUTRAL-to-BULLISH]

Multi-item earnings release (2.02 + 7.01 Reg FD, materiality 5/10) reflects proactive disclosure, low risk profile supports relative outperformance vs opaque peers

Earnings filing (Item 2.02, materiality 6/10, low risk) amid REIT peers signals consistent reporting, no capital allocation disruptions noted [NEUTRAL-to-BULLISH]

Item 5.07 shareholder vote submission (materiality 3/10, low risk) with no contentious outcomes disclosed implies strong governance conviction

Reg FD disclosure (Item 7.01) alongside material agreement suggests positive strategic updates, high materiality 8/10 offsets dilution concerns

Item 8.01 other events (materiality 3/10, low risk) in AI sector indicates potential tech catalyst without red flags [NEUTRAL-to-BULLISH]

Voluntary 8-K filing (8.01, materiality 2/10) reflects proactive communication in pharma, low risk vs sector volatility

Low materiality other event (2/10) with neutral sentiment positions as stable healthcare play absent negative trends [NEUTRAL-to-BULLISH]

Officer changes disclosure (Item 5.02, materiality 5/10) could signal refreshed leadership, medium risk but no financial hits

Both earnings filings show higher materiality (5/10 vs avg 4.8/10), relative outperformance in timely multi-item disclosures

Unregistered equity sales (Item 3.02, medium risk, materiality 8/10) flag potential shareholder dilution and financing needs, lacks transaction size details

Material definitive agreement (Item 1.01) without terms, valuations, or timelines disclosed heightens unknown risks

Departure/election of officers/directors (Item 5.02, medium risk, materiality 5/10) without reasons or key positions raises leadership stability concerns

Item 8.01 other events lacks specifics, critical details undisclosed (materiality 3/10)

No event details in 8.01 filing increases opacity for small-cap pharma (materiality 2/10)

Earnings 8-K (2.02) without revenue/earnings data limits operational health assessment (materiality 5/10)

Earnings + Reg FD without period comparisons or guidance exposes to hidden QoQ declines (materiality 5/10)

Shareholder vote (5.07) lacks outcome details, potential hidden contentious issues (materiality 3/10)

Item 8.01 other events with no transaction/financial impacts (materiality 2/10)

Earnings filing absent YoY trends or ratios flags incomplete view of REIT health (materiality 6/10)

High materiality 7/10 Item 2.02 filing positions for post-disclosure alpha if exhibits reveal YoY growth beats, low risk entry

Item 7.01 disclosure offers forward-looking potential absent in peers, monitor for guidance upside vs neutral sentiment

Earnings release (6/10 materiality) in low-risk profile suits dividend-focused portfolios, watch capital allocation exhibits

Clean shareholder vote filing (low risk) supports long-term conviction play, relative to higher-risk peers

Material agreement (8/10 materiality) could unlock synergies if details positive, outweighs dilution if accretive

Timely earnings 8-K allows pairing with sector tailwinds, low risk for growth rotation

Other events filing in AI space (low risk) flags early catalyst ahead of peers

Proactive low-materiality filing suggests undervalued entry vs biotech volatility

Officer changes as potential inflection for operational metrics improvement

Minimal risk other event enables relative value vs higher-risk healthcare filings

4/10 filings (Keurig, CCC, CoStar, SUN) are Item 2.02 earnings-related on same day, avg materiality 5.75/10, signals NASDAQ-100 Q4'25 reporting kickoff with low risk, watch for portfolio margin trends

50% (5/10) Item 8.01 other events (AI Tech, Adial, Veradigm) lack details, neutral sentiment but elevates uncertainty vs detailed peers, implication: avoid until exhibits clarified

AMD's material agreement + equity sales (8/10 materiality) amid AI Tech filing highlights tech M&A/dilution pattern, medium risk flags financing for growth

Bravo (5.02) and Apple (5.07) represent management/vote disclosures (avg materiality 4/10), low-medium risk but watch for insider conviction patterns

80% low risk across filings (avg materiality 4.8/10) vs 2 medium, suggests stable NASDAQ-100 non-financials absent capital allocation stress

10/10 neutral, no bullish/bearish outliers, implies no major period-over-period disruptions but lacks enriched data for relative performance gaps

Monitor for deal terms, M&A valuations, timelines in exhibits; potential dilution impact from equity sales [Feb 24, 2026 ongoing]

Track Item 9.01 financials for YoY revenue/margins, guidance changes post-filing [Immediate review]

Watch Item 7.01 for forward-looking statements, operational metrics vs real estate peers [Feb 24 exhibits]

Follow-up on officer identities, compensatory arrangements for insider activity signals [Next 30 days]

Earnings exhibits for capacity, debt ratios, dividend updates amid low-risk profile [Immediate]

Review undisclosed results for insurtech growth trends, no prior QoQ declines noted [Feb 24]

Details on director elections, compensation approvals for governance conviction [Exhibits review]

Clarify Item 8.01 details for AI sector catalysts [Ongoing monitoring]